These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31711926)

  • 41. Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.
    Alves GS; Freire AK; Bentes Ados S; Pinheiro JF; de Souza JV; Wanke B; Matsuura T; Jackisch-Matsuura AB
    Mycoses; 2016 Aug; 59(8):509-15. PubMed ID: 27005969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
    Silva DC; Martins MA; Szeszs MW; Bonfietti LX; Matos D; Melhem MS
    Diagn Microbiol Infect Dis; 2012 Apr; 72(4):332-9. PubMed ID: 22341512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microevolution of Serial Clinical Isolates of
    Chen Y; Farrer RA; Giamberardino C; Sakthikumar S; Jones A; Yang T; Tenor JL; Wagih O; Van Wyk M; Govender NP; Mitchell TG; Litvintseva AP; Cuomo CA; Perfect JR
    mBio; 2017 Mar; 8(2):. PubMed ID: 28270580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Small Animal Aspergillosis and Cryptococcosis in Japan].
    Kano R
    Med Mycol J; 2017; 58(4):J121-J126. PubMed ID: 29187719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pyrifenox, an ergosterol inhibitor, differentially affects Cryptococcus neoformans and Cryptococcus gattii.
    Silva VKA; May RC; Rodrigues ML
    Med Mycol; 2020 Oct; 58(7):928-937. PubMed ID: 31915833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis.
    Kano R; Okubo M; Yanai T; Hasegawa A; Kamata H
    Mycopathologia; 2015 Dec; 180(5-6):427-33. PubMed ID: 26162642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
    Vu K; Gelli A
    Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
    Li M; Liao Y; Chen M; Pan W; Weng L
    Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
    Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
    Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disseminated Cryptococcus deuterogattii (AFLP6/VGII) infection in an Arabian horse from Dubai, United Arab Emirates.
    Kinne J; Joseph M; Wernery U; Nogradi N; Hagen F
    Rev Iberoam Micol; 2017; 34(4):229-232. PubMed ID: 28595777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiological, Clinical and Outcome Aspects of Patients with Cryptococcosis Caused by Cryptococcus gattii from a Non-endemic Area of Brazil.
    Damasceno-Escoura AH; de Souza ML; de Oliveira Nunes F; Pardi TC; Gazotto FC; Florentino DH; Mora DJ; Silva-Vergara ML
    Mycopathologia; 2019 Feb; 184(1):65-71. PubMed ID: 30415450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
    Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
    Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
    Trilles L; Meyer W; Wanke B; Guarro J; Lazéra M
    Med Mycol; 2012 Apr; 50(3):328-32. PubMed ID: 21859388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular epidemiology and antifungal susceptibility profiles of clinical
    Bandalizadeh Z; Shokohi T; Badali H; Abastabar M; Babamahmoudi F; Davoodi L; Mardani M; Javanian M; Cheraghmakani H; Sepidgar AA; Badiee P; Khodavaisy S; Afshari SAK; Ahmadikia K; Seyedmousavi S
    J Med Microbiol; 2020 Jan; 69(1):72-81. PubMed ID: 31750814
    [No Abstract]   [Full Text] [Related]  

  • 57. Characterization of clinical isolates of the Cryptococcus neoformans-Cryptococcus gattii species complex from the Amazonas State in Brazil.
    Da Silva BK; Freire AK; Bentes Ados S; Sampaio Ide L; Santos LO; Dos Santos MS; De Souza JV
    Rev Iberoam Micol; 2012; 29(1):40-3. PubMed ID: 21699993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.
    Lockhart SR; Fothergill AW; Iqbal N; Bolden CB; Grossman NT; Garvey EP; Brand SR; Hoekstra WJ; Schotzinger RJ; Ottinger E; Patterson TF; Wiederhold NP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2528-31. PubMed ID: 26787697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum.
    Brummer E; Kamei K; Miyaji M
    Mycopathologia; 1998; 142(1):3-7. PubMed ID: 9850592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.